首页 | 本学科首页   官方微博 | 高级检索  
     

甲胎蛋白对索拉菲尼治疗进展期肝细胞癌的预后评价
引用本文:金 超,杜锡林,鲁建国. 甲胎蛋白对索拉菲尼治疗进展期肝细胞癌的预后评价[J]. 现代肿瘤医学, 2015, 0(18): 2705-2708. DOI: 10.3969/j.issn.1672-4992.2015.18.47
作者姓名:金 超  杜锡林  鲁建国
作者单位:第四军医大学唐都医院普通外科,陕西 西安 710038
摘    要:近几年来以索拉菲尼为代表的分子靶向药物已成为进展期肝细胞癌综合治疗的热点之一,但目前对于索拉菲尼治疗进展期肝细胞癌的预后评价指标尚没有统一的标准。甲胎蛋白作为重要的肝癌肿瘤标志物,已经广泛地应用于肝细胞癌的筛查诊断,并被认为具有潜在的预测肝细胞癌患者的预后价值。本文总结了近几年来关于甲胎蛋白对索拉菲尼治疗进展期肝细胞癌预后评价的相关文献。从总体上看,甲胎蛋白对于索拉菲尼治疗进展期肝细胞癌预后评价作用是值得肯定的,并可以作为传统的基于影像学资料的肝细胞癌预后评价标准的补充,具有广泛的研究前景和应用价值。

关 键 词:甲胎蛋白  索拉菲尼  进展期肝细胞癌

Prognostic evaluation of AFP in advanced hepatocellular carcinoma treated with sorafenib
Jin Chao,Du Xilin,Lu Jianguo. Prognostic evaluation of AFP in advanced hepatocellular carcinoma treated with sorafenib[J]. Journal of Modern Oncology, 2015, 0(18): 2705-2708. DOI: 10.3969/j.issn.1672-4992.2015.18.47
Authors:Jin Chao  Du Xilin  Lu Jianguo
Affiliation:Department of General Surgery,TangDu Hospital,Fourth Military Medical University,Shaanxi Xi'an 710038,China.
Abstract:In recent years,targeted drugs like sorafenib have been the hotspot of comprehensive treatment of advanced hepatocellular carcinoma(HCC).However,there is not comprehensive evaluation indexes for the prognosis of advanced HCC.AFP(Alpha-fetoprotein) has been proved an important marker of HCC.And it is also thought to be possible in predicting prognostic of patients with advanced hepatocellular carcinoma.We summarize the relevant literatures about the prognostic evaluation of AFP in advanced HCC treated with sorafenib in recent years.It should be affirmed that the prognostic evaluation of AFP in advanced HCC treated with sorafenib.AFP can also be used as a supplement for the traditional evaluation criteria of HCC based on imaging studies.The significance of AFP as an predictor for prognosis of HCC treated with sorafenib is considerable in research and clinical application.
Keywords:AFP  sorafenib  advanced hepatocellular carcinoma
本文献已被 万方数据 等数据库收录!
点击此处可从《现代肿瘤医学》浏览原始摘要信息
点击此处可从《现代肿瘤医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号